# Seiji Niho

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/seiji-niho/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,703 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 43 |
| i10-index | 123 |
| Last Known Institution | Dokkyo Medical University |
| OpenAlex ID | https://openalex.org/A5043607755 |
| ORCID iD | 0000-0001-9480-5923 |
| Works | 398 |

## Researcher papers

- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations](https://scholariq.org/papers/improvement-in-overall-survival-in-a-randomized-study-that-compared-dacomitinib/)
- [Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis](https://scholariq.org/papers/therapeutic-priority-of-the-pi3k-akt-mtor-pathway-in-small-cell-lung-cancers-as/)
- [Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer](https://scholariq.org/papers/randomized-phase-ii-study-of-first-line-carboplatin-paclitaxel-with-or-without/)
- [Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial](https://scholariq.org/papers/lenvatinib-in-patients-with-advanced-or-metastatic-thymic-carcinoma-remora-a/)
- [Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung](https://scholariq.org/papers/genomic-profiling-of-large-cell-neuroendocrine-carcinoma-of-the-lung/)
- [First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study](https://scholariq.org/papers/first-line-single-agent-treatment-with-gefitinib-in-patients-with-advanced-non/)
- [Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study](https://scholariq.org/papers/combination-chemotherapy-with-irinotecan-and-cisplatin-for-large-cell/)
- [Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients](https://scholariq.org/papers/pitfalls-in-lymph-node-staging-with-positron-emission-tomography-in-non-small/)
- [Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation](https://scholariq.org/papers/podoplanin-positive-cancer-associated-fibroblasts-in-the-tumor-microenvironment/)
- [Abstract 4920: A status of re-biopsy for non-small-cell lung cancer patients after first EGFR-TKI failure and incidence of T790M mutation](https://scholariq.org/papers/abstract-4920-a-status-of-re-biopsy-for-non-small-cell-lung-cancer-patients/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Dokkyo Medical University](https://scholariq.org/institutions/dokkyo-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.